menu
    • menu
    [{"orgOrder":0,"company":"EG 427","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$20.2 million","upfrontCash":"Undisclosed","newsHeadline":"EG 427 Announces Final Series a Closing, Achieving \u20ac18 Million in Total Funds Raised","therapeuticArea":"Urology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Series A Financing","leadProduct":"EG110A","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0.02,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"EG 427 \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Undisclosed"},{"orgOrder":0,"company":"EG 427","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)","therapeuticArea":"Urology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"EG110A","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"IND Enabling","graph3":"EG 427","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EG 427 \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"EG 427 \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EG 427

                            France arrow
                            World Dairy Expo 2024
                            Not Confirmed

                            EG 427

                            France arrow
                            World Dairy Expo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG110A

                            Therapeutic Area : Urology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (N...

                            Details : EG110A is based on company's unique non-replicative HSV-1 vector platform. It is being evaluated in preclinical studies for the treatment of neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).

                            Brand Name : EG110A

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 04, 2024

                            Lead Product(s) : EG110A

                            Therapeutic Area : Urology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EG 427

                            France arrow
                            World Dairy Expo 2024
                            Not Confirmed

                            EG 427

                            France arrow
                            World Dairy Expo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EG110A

                            Therapeutic Area : Urology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $20.2 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            EG 427 Announces Final Series a Closing, Achieving €18 Million in Total Funds Raised

                            Details : The funding will be used to advance company's pipeline, culminating in the Investigational New Drug application filing for the first clinical study of its lead product, EG110A which targets the silencing of type-C sensory neuronsm and is being developed ...

                            Brand Name : EG110A

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 13, 2023

                            Lead Product(s) : EG110A

                            Therapeutic Area : Urology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $20.2 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth